




bionano™

# Q1'26 Financial Results Webcast & Call

May 13, 2026




# Cautionary Note Regarding Forward-Looking Statements


This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our expectations regarding market adoption of our products; our commercial prospects and future financial and operating results; and our ability to meet our stated goals and commercial opportunities, including our full year and first quarter 2026 guidance. Each of these forward-looking statements involves risks and uncertainties. Accordingly, investors and prospective investors are cautioned not to place undue reliance on these forward-looking statements as they involve inherent risk and uncertainty (both general and specific) and should note that they are provided as a general guide only and should not be relied on as an indication or guarantee of future performance. There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include, but are not limited to: our ability to improve our margins, extend our cash runway and reach a potential pathway to profitability; our ability to retire our debt at maturity; our ability to continue as a going concern as disclosed in our filings with the SEC, which requires us to manage costs and obtain significant additional financing to fund our strategic plans and commercialization efforts; our ability to execute on our strategy and achieve our objectives; the impact and utility of our cost savings initiative and our recent financing; our ability to continue to drive OGM (as defined above) adoption by potential customers for routine use in genomic analysis; the impact, or lack thereof, of Category I CPT codes to accelerate or increase the adoption of OGM; continued research, presentations and publications involving OGM and its utility compared to traditional cytogenetics and our technologies; the impact of our Stratys™ system and VIA™ software to increase throughput and simplify analysis of OGM data; our ability to drive adoption of OGM and our technology solutions; our ability to further deploy new products and applications for our technology platforms; our expectations and beliefs regarding future growth of the business and the markets in which we operate; our ability to consummate any strategic alternatives including the risk that if we fail to obtain additional financing we may seek relief under applicable insolvency laws; the size and growth potential of the markets for our products, and our ability to serve those markets; the rate and degree of market acceptance of our products; our ability to manage the growth of our business and integrate acquired businesses; our ability to expand our commercial organization to address effectively existing and new markets that we intend to target; the impact from future regulatory, judicial, and legislative changes or developments in the U.S. and foreign countries; our ability to compete effectively in a competitive industry; the introduction of competitive technologies or improvements in existing technologies and the success of any such technologies; the performance of our third-party contract sales organizations, suppliers and manufacturers; our ability to attract and retain key scientific or management personnel; the accuracy of our estimates regarding expenses, future revenues, reimbursement rates, capital requirements and needs for additional financing; the impact of adverse geopolitical and macroeconomic developments, such as recent and future bank failures, ongoing international conflicts, and related sanctions, regional or global pandemics, inflation, tariffs, increased cost of goods, supply chain issues, and global financial market conditions on our business and operations, as well as the business or operations of our suppliers, customers, manufacturers, research partners and other third parties with whom we conduct business and our expectations with respect to the duration of such impacts and the resulting effects on our business; our ability to realize the anticipated benefits and synergies of our prior and any future acquisitions or other strategic transactions; our ability to attract collaborators and strategic partnerships; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission (“SEC”), including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2025, any subsequently filed Quarterly Reports on Form 10-Q and in other filings subsequently made by us with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as may be required by law.

GAAP reconciliation of adjusted financial measures can be found in the Appendix and our earnings release.

# Bionano is among the leaders transforming pathology from its analog roots into a more digital future




# Strategic pillars



# Q1 2026 consumables revenue showed growth, in line with our strategy to focus on routine users


## Flowcells Sold

- In connection to new customer sales
- To existing customer base



## Revenue Mix

- Other revenue
- Software revenue
- Consumables revenue



# Upgrades to software and compute platforms to make analysis of OGM, microarray, and NGS data easier, faster, and more accurate

## Software Platforms

### VIA™ 7.2

Broadens OGM workflow to include constitutional genetic disorders, building upon existing capabilities in hematological malignancies

### Solve™ 3.8.3

Expands structural variant (SV) control database and improves accuracy and performance across key areas, including sensitivity, specificity, and resolution for SV detection

## Compute Platforms

### Stratus™ Compute

Can double the throughput and enable twice the number of samples to be processed per week with server upgraded to use advanced GPUs for OGM data analysis



**Broad commercial release completed in Q4 2025**

# Effective Jan 1, 2026, a CPT code covering OGM in genetic disorders and a 47% price increase for code used for hematologic malignancies

## AMA CPT Code for OGM in Constitutional Genetic Disorders (new in 2026)

Current Code # 81354

Code Type NEW

Category Molecular Pathology;  
Optical Genome Mapping

Long Code Descriptor Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of structural and copy number variants, optical genome mapping (OGM)

**Final payment determination effective Jan 1, 2026:  
\$1,263.53**

## AMA CPT Code for OGM in Hematologic Malignancies (47% price increase in 2026)

Current Code # 81195

Code Type NEW 2024;  
Payment reconsidered 2025

Category Molecular Pathology;  
Optical Genome Mapping


Long Code Descriptor Cytogenomic (genome-wide) analysis, hematologic malignancy, structural variants and copy number variants, optical genome mapping (OGM)

**Reconsidered payment determination effective Jan 1, 2026: \$1,853.22 (47% increase)**

CPT = Current Procedural Terminology


# On track for record number of new publications in 2026 with growing number of published human clinical research genomes

117 new publications in Q1 2026 across a range of applications



New Publication CAGR (2020-2025): 28%

1,991 human clinical research genomes published in Q1 2026 reaching nearly 14,700 in total




Published Genome CAGR (2021-2025): 30%+

# Healthy cost structure sustains following substantial improvements over the last two years

Decreased adjusted operating expenses<sup>1</sup>  
by 6% Q/Q in Q1 2026

Adjusted Operating Expenses Trend (\$M)




Improved adjusted gross margin<sup>1</sup> to 49%  
in Q1 2026, compared to adjusted core gross  
margin of 46%<sup>2</sup> in Q1 2025

Adjusted Core Gross Margin<sup>2</sup> Trend (%)



# Q1 2026 Results

<p><b>\$6.7M</b> Q1 Revenue</p> <p>+4% vs. Q1'25</p>	<p><b>8,178</b> Q1 Flowcells Sold</p> <p>+17% vs. Q1'25</p>	<p><b>49%</b> Q1 Adjusted Gross Margin</p> <p>+300 bps vs. Q1'25</p>
--	---	--



**\$24.7M<sup>1</sup> cash, cash equivalents, and available-for-sale securities as of March 31, 2026**

1. \$10.3M subject to certain restrictions

# 2026 Guidance



**Reiterating FY'26 revenue: \$30 – \$33M**



**Initiating Q2'26 revenue: \$7.5 – \$7.8M**

***Cash Runway into 2027***



**Thank you.**

bionano™

# Statement regarding use of adjusted financial measures

Effective with the fiscal period ended March 31, 2026, the Company renamed certain of its non-GAAP financial measures. Measures previously reported as "non-GAAP gross margin," "non-GAAP operating expense," and other titles using "non-GAAP" are now presented as "adjusted gross margin," "adjusted operating expense," and similar designations, respectively. These title changes are intended solely to simplify the Company's presentation and align with the nomenclature commonly used by the Company's peers. The definitions, methodologies, and components underlying each of these measures remain unchanged from prior periods, and no adjustments have been made to the items included in, or excluded from, the calculation of any such measure on account of the title changes. Prior-period amounts and descriptions have been recast to conform to the current-period presentation.

To supplement Bionano's financial results reported in accordance with U.S. generally accepted accounting principles (GAAP), the Company has provided adjusted gross margin and adjusted operating expense in this presentation, each of which is a non-GAAP financial measure. The most directly comparable GAAP measures to these adjusted financial measures are gross margin, cost of revenue, selling, general and administrative expense, research and development expense, intangible assets and other long-lived assets impairment, restructuring costs and operating expense, each as reported in accordance with GAAP. Adjusted gross margin excludes from gross margin reported in accordance with GAAP: stock-based compensation and restructuring expenses, and impairment and disposal of reagent rentals and inventory. Adjusted operating expense excludes from operating expense reported in accordance with GAAP: stock-based compensation, amortization of intangibles, changes in fair value of contingent consideration, transaction-related expenses, and loss on disposals. In addition, our reconciliation table provided at the end of this presentation contains certain additional adjusted metrics, including adjusted cost of revenue, adjusted selling, general and administrative expense, adjusted research and development expense, adjusted intangible assets and other long-lived assets impairment and adjusted restructuring costs, each with adjustments as presented in the table. Stock-based compensation and certain other items excluded from our adjusted financial measures are recurring expenses for us and are expected to continue in future periods.

Bionano believes that each of these adjusted metrics is useful to investors and analysts as a supplement to its financial information prepared in accordance with GAAP for analyzing the Company's performance and identifying trends in its business. Bionano uses these adjusted metrics internally to facilitate period-to-period comparisons and analysis of its performance in order to understand, manage and evaluate its business, to make operating decisions, and for forecasting and budgeting. Accordingly, Bionano believes presentation of these adjusted measures allow for greater transparency with respect to key financial metrics it uses in assessing its own operating performance and making operating decisions.

These adjusted financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future, there may be other items that the Company may exclude for purposes of its adjusted financial measures; and the Company may in the future cease to exclude items that it has historically excluded for purposes of its adjusted financial measures. Likewise, the Company may determine to modify the nature of its adjustments to arrive at its adjusted financial measures. Because of the non-standardized definitions of adjusted financial measures, each adjusted financial measure as used by Bionano in this presentation has limits in its usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.

For a reconciliation of adjusted gross margin to gross margin reported in accordance with GAAP and adjusted operating expense to operating expense reported in accordance with GAAP, please refer to the financial tables accompanying this presentation.

# Reconciliation of GAAP to Adjusted Financial Measures (Unaudited)

## Bionano Genomics, Inc. Reconciliation of GAAP to Adjusted Financial Measures (Unaudited)

	Three Months Ended March 31,	
	2026	2025
GAAP gross margin:		
GAAP revenue	\$ 6,687	\$ 6,457
GAAP cost of revenue	3,435	3,519
GAAP gross profit	3,252	2,938
GAAP gross margin %	49%	46%
Adjusted gross margin:		
GAAP revenue	\$ 6,687	\$ 6,457
GAAP cost of revenue	3,435	3,519
Stock-based compensation expense	(31)	(37)
Adjusted cost of revenue	3,404	3,482
Adjusted gross profit	3,283	2,975
Adjusted gross margin %	49%	46%
GAAP operating expense		
GAAP selling, general and administrative expense	\$ 8,010	\$ 9,033
Stock-based compensation expense	(561)	(1,300)
Intangible asset amortization	(1,340)	(1,340)
Transaction related expenses	(100)	(63)
Adjusted selling, general and administrative expense	6,009	6,330
GAAP research and development expense	\$ 3,139	\$ 2,370
Stock-based compensation expense	(78)	(250)
Adjusted research and development expense	3,061	2,120
Total adjusted operating expense	\$ 9,070	\$ 8,450